Sumitomo Mitsui Trust Group Inc. Acquires 13,311 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Sumitomo Mitsui Trust Group Inc. raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 4.2% during the fourth quarter, Holdings Channel reports. The institutional investor owned 327,763 shares of the biopharmaceutical company’s stock after buying an additional 13,311 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Alnylam Pharmaceuticals were worth $130,335,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Vanguard Group Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 2.0% in the third quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock valued at $6,185,846,000 after buying an additional 268,313 shares in the last quarter. Capital Research Global Investors lifted its position in shares of Alnylam Pharmaceuticals by 0.4% during the third quarter. Capital Research Global Investors now owns 7,222,840 shares of the biopharmaceutical company’s stock valued at $3,293,516,000 after purchasing an additional 31,184 shares in the last quarter. Groupama Asset Managment lifted its position in shares of Alnylam Pharmaceuticals by 160.4% during the third quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock valued at $18,610,000 after purchasing an additional 2,483,697 shares in the last quarter. Orbis Allan Gray Ltd lifted its position in shares of Alnylam Pharmaceuticals by 29.8% during the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock valued at $691,771,000 after purchasing an additional 486,489 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its position in shares of Alnylam Pharmaceuticals by 698.8% during the third quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company’s stock valued at $618,158,000 after purchasing an additional 1,185,909 shares in the last quarter. 92.97% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, insider Melissa Mclaughlin sold 2,286 shares of the business’s stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $330.42, for a total value of $755,340.12. Following the sale, the insider owned 9,443 shares of the company’s stock, valued at $3,120,156.06. The trade was a 19.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Kevin Joseph Fitzgerald sold 1,652 shares of the business’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $319.73, for a total transaction of $528,193.96. Following the completion of the sale, the executive vice president directly owned 21,860 shares in the company, valued at approximately $6,989,297.80. This trade represents a 7.03% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 38,656 shares of company stock valued at $12,370,696. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $333.00 on Tuesday. The firm has a market cap of $44.43 billion, a price-to-earnings ratio of 194.74 and a beta of 0.39. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76. Alnylam Pharmaceuticals, Inc. has a 52 week low of $225.84 and a 52 week high of $495.55. The firm’s 50-day simple moving average is $324.05 and its two-hundred day simple moving average is $389.34.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The business had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.16 billion. During the same quarter in the previous year, the business earned ($0.65) EPS. Alnylam Pharmaceuticals’s revenue for the quarter was up 84.9% on a year-over-year basis. As a group, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on ALNY. Bank of America reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 12th. Oppenheimer began coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, January 7th. They set an “outperform” rating and a $500.00 price target on the stock. Canaccord Genuity Group raised their price target on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. Barclays began coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, January 28th. They set an “overweight” rating and a $527.00 price target on the stock. Finally, Truist Financial dropped their price target on shares of Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating on the stock in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $472.78.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.